The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

The lawsuit, filed by the Outsourcing Facilities Association , FarmaKeio Custom Compounding and North American Custom Laboratories in the U.S. District Court for the Northern District of Texas, argues ...

Hims & Hers (NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

European stocks are soaring as American markets stay choppy. With more European military spending on the horizon, defense ...

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...

CDC staff received an email this week telling them to avoid using more than a dozen terms or words -- including "health ...

More than 50 people have died in the Democratic Republic of the Congo, most within 48 hours of the onset of symptoms. Initial analysis suggests neither Ebola nor Marburg is the cause.